Antimicrobial stewardship - Can we afford to do without it?

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 173-181

  Aryee, Anna ^a   Price, Nicholas ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

antibiotic resistance; antibiotic stewardship; antimicrobial resistance; antimicrobial stewardship

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL RESEARCH; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; LEADERSHIP; LOWEST INCOME GROUP; MEDICATION COMPLIANCE; MIDDLE INCOME GROUP; MISCELLANEOUS NAMED GROUPS; POLITICS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESPONSIBILITY; SOCIAL MEDIA; CLINICAL PRACTICE; DEVELOPING COUNTRY; HEALTH; OUTCOME ASSESSMENT; STANDARDS;

ANTI-INFECTIVE AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; GLOBAL HEALTH; HEALTH CARE COSTS; HUMANS; PATIENT OUTCOME ASSESSMENT; PRACTICE PATTERNS, PHYSICIANS';

EID: 84943567758     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12417     Document Type: Article

References (49)

1. Cosgrove SE, Carmeli Y,. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 1433; 36: 1433-1437.
2. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP,. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006; 27: 1226-1232.
3. John JF, Fishman NO,. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24: 471-485.
4. Smolinski MS, Hamburg MA, Lederberg J, eds. Microbial Threats to Health: Emergence, Detection, and Response. Washington: National Academies Press, 2003.
5. World Health Organisation. Medicines: rational use of medicines [online]. WHO Factsheet no 338. Geneva: World Health Organisation, 2010. Available at http://www.who.int/mediacentre/factsheets/fs338/en/ (last accessed 5 December 2013).
6. Cornaglia G, Giamarellou H, Rossolini GM,. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 2011; 11: 381-393.
7. Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52 (Suppl. 5): S397-S428.
8. Ohl CA, Dodds Ashley ES,. Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis 2011; 53 (Suppl. 1): S23-S28; quiz S29-S30.
9. Bantar C, Sartori B, Vesco E, Heft C, Saúl M, Salamone F, Oliva ME,. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180-186.
10. Cheng VC, To KK, Li IW, Tang BS, Chan JF, Kwan S, Mak R, Tai J, Ching P, Ho PL, Seto WH,. Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur J Clin Microbiol Infect Dis 2009; 28: 1447-1456.
11. Hand K,. Antibiotic stewardship. Clin Med 2013; 13: 499-503.
12. Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M,. Antibiotic resistance-the interplay between antibiotic use in animals and human beings. Lancet Infect Dis 2003; 3: 47-51.
13. Van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M,. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 1722-1730.
14. Chen DK, McGeer A, de Azavedo JC, Low DE,. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
15. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD,. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340: c2096.
16. Duffy M, Hernandez-Santiago V, Orange G, Davey PG, Guthrie B,. Trimethoprim prescription and subsequent resistance in childhood urinary infection: multilevel modelling analysis. Br J Gen Pract 2013; 63: e238-243.
17. Gonzales R, Malone DC, Maselli JH, Sande MA,. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33: 757-762.
18. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ,. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163: 972-978.
19. Cusini A, Rampini SK, Bansal V, Ledergerber B, Kuster SP, Ruef C, Weber R,. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS ONE 2010; 5: e14011.
20. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendez A, Klugman KP,. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005; 5: 481-493.
21. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendez A, Laxminarayan R,. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 2005; 5: 568-580.
22. Country pharmaceutical situations: fact book on WHO level 1 indicators 2007 [online]. Geneva: World Health Organization, 2009. Available at http://apps.who.int/medicinedocs/index/assoc/s16874e/s16874e.pdf (last accessed 5 December 2013).
23. Medicines use in primary care in developing and transitional countries? Fact book summarizing results from studies reported between 1990 and 2006 [online]. Geneva: World Health Organization, 2009. Available at http://apps.who.int/medicinedocs/documents/s16073e/s16073e.pdf (last accessed 5 December 2013).
24. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S,. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011; 11: 692-701.
25. Newton PN, Green MD, Fernández FM, Day NPJ, White NJ,. Counterfeit anti-infective drugs. Lancet Infect Dis 2006; 6: 602-613.
26. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME,. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007; 60: 214-236.
27. Chapter 3: measures to ensure better use of antibiotics. The evolving threat of antimicrobial resistance: options for action [online]. Geneva: WHO Library Cataloguing-in-Publication Data, 2012. Available at http://whqlibdoc.who.int/publications/2012/9789241503181-eng.pdf (last accessed 7 December 2013).
28. Wirtz VJ, Dreser A, Gonzales R,. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica 2010; 27: 219-225.
29. Tham J, Odenholt I, Walder M, Andersson L, Melander E,. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli in a county in Southern Sweden. Infect Drug Resist 2013; 6: 93-97.
30. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JDD,. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008; 57: 441-448.
31. ProMED-mail: PRO/EDR> Antimicrobial resistance-Netherlands ex Egypt: family [online]. Louisiana: ProMED-mail, 2013. Available at http://www.promedmail.org/direct.php?id=20131018.2008610 (last accessed 2 December 2013).
32. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322-327.
33. Fishman N,. Antimicrobial stewardship. Am J Med 2006; 119: S53-S61.
34. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB,. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25: 230-239.
35. Corona A, Bertolini G, Lipman J, Wilson AP, Singer M,. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65: 1276-1285.
36. UK Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections. Antimicrobial Stewardship: 'Start Smart-then Focus'. 2011.
37. Meropol SB, Localio AR, Metlay JP,. Risks and benefits associated with antibiotic use for acute respiratory infections: a cohort study. Ann Fam Med 2013; 11: 165-172.
38. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, Holmes A, Ramsay C, Taylor E, Wilcox M, Wiffen P,. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; 4: CD003543.
39. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM,. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65: 2141-2148.
40. Srinivasan A, Song X, Richards A, Sinkowitz-Cochran R, Cardo D, Rand C,. A survey of knowledge, attitudes, and beliefs of house staff physicians from various specialties concerning antimicrobial use and resistance. Arch Intern Med 2004; 164: 1451-1456.
41. Pulcini C, Williams F, Molinari N, Davey P, Nathwani D,. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect 2011; 17: 80-87.
42. Holloway K,. Essential drugs monitor 2000 [online]. Geneva: WHO, 2000; 16-18. Available at http://apps.who.int/medicinedocs/pdf/s2248e/s2248e.pdf (last accessed 12 December 2013).
43. Management Sciences for Health, Arlington VA. Interventions and strategies to improve the use of antimicrobials in developing countries: a review [online]. Geneva: World Health Organization, 2001. Available at http://whqlibdoc.who.int/hq/2001/who-CDS-CSR-DRS-2001.9.pdf (last accessed 7 December 2013).
44. Bosso JA, Drew RH,. Application of antimicrobial stewardship to optimise management of community acquired pneumonia. Int J Clin Pract 2011; 65: 775-783.
45. A single competency framework for all prescribers [online]. London: National Prescribing Centre, provided by NICE, 2012. Available at http://www.npc.co.uk/improving-safety/improving-quality/resources/single-comp-framework.pdf (last accessed 19 December 2013).
46. Effective antibiotic prescribing-top ten tips. Royal College of Physicians Healthcare Associated Infections Working Group. 2011.
47. UK five year antimicrobial resistance strategy 2013 to 2018. London: Department of Health, 2013. Available at https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/244058/20130902-UK-5-year-AMR
48. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, Pérez-Vázquez M, Alcaraz M, García-Cobos S, Campos J,. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64: 712-717.
49. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, Pérez-Vázquez M, Alcaraz M, García-Cobos S, Campos J,. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64: 712-717.